Shorts on low level, page-10

" at $1+ " is not so bad a deal, IMO. for a US$36M market cap company having a 15-year license of PBT2 to prevent the development of antibiotic resistance practically in all otitis infections, in all pneumonia, urine infections, all gonorrhea cases, etc. ( total present market perhaps some 40B). Every treatment of these infections needs to be treated with a combination of PBT2 and the selected antibiotic to avoid the development of antibiotic resistance and then causing death every year to over 1 million people.
PBT2 will add some cost to some of the treatments but it will also reduce the cost when simple antibiotics such as penicillins, tetracyclines, etc will start working. Every antibiotic company will need PBT2 in all parts of the world to control antibiotic-resistant problems.
I have no skills to calculate the value of PBT2 but my guess is that it can be up to 10B / year in the world because it can easily save this amount of money by reducing death and suffering and also the costs to the societies ( in the USA some $ 1.9B).

So, " at $ 1+ " is a good deal, IMO.
I think that Uniquest will target the real value of PBT2 based on the decrease in deaths and suffering and the savings to the societies. For this US$10 B is not too much within one year, just in my opinion.